SLC1A5 and cancer: V9302 was originally developed as a potent small-molecule inhibitor of the glutamine transporter ASCT2 (SLC1A5) in mammalian cells, where it was shown to block glutamine uptake and suppress cancer cell growth in preclinical models [31].